Zacks Investment Research upgraded shares of Vascular Biogenics (NASDAQ:VBLT) from a sell rating to a hold rating in a research report sent to investors on Saturday, January 6th.
According to Zacks, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. “
VBLT has been the topic of several other research reports. HC Wainwright reissued a buy rating and issued a $11.00 price objective on shares of Vascular Biogenics in a research report on Tuesday, November 21st. Chardan Capital upped their price target on Vascular Biogenics from $20.00 to $25.00 and gave the company a buy rating in a research report on Monday, November 6th. Finally, ValuEngine cut Vascular Biogenics from a hold rating to a sell rating in a research report on Wednesday, September 27th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Vascular Biogenics presently has a consensus rating of Hold and an average target price of $15.67.
Vascular Biogenics (VBLT) traded down $0.20 during midday trading on Friday, hitting $8.30. The stock had a trading volume of 281,233 shares, compared to its average volume of 210,364. Vascular Biogenics has a 52-week low of $3.90 and a 52-week high of $9.05.
A hedge fund recently bought a new stake in Vascular Biogenics stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Vascular Biogenics Ltd (NASDAQ:VBLT) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 22,100 shares of the biopharmaceutical company’s stock, valued at approximately $135,000. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.08% of Vascular Biogenics as of its most recent SEC filing. 6.59% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Vascular Biogenics (VBLT) Upgraded at Zacks Investment Research” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/01/13/vascular-biogenics-vblt-lifted-to-hold-at-zacks-investment-research.html.
About Vascular Biogenics
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Get a free copy of the Zacks research report on Vascular Biogenics (VBLT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.